Modality
Multispecific
MOA
GLP-1ag
Target
GPRC5D
Pathway
RNA Splicing
DMDIPFCRC
Development Pipeline
Preclinical
~Dec 2013
→ ~Mar 2015
Phase 1
~Jun 2015
→ ~Sep 2016
Phase 2
~Dec 2016
→ ~Mar 2018
Phase 3
Jun 2018
→ May 2027
Phase 3Current
NCT06320389
1,434 pts·CRC
2018-06→2025-01·Terminated
NCT04122419
2,511 pts·DMD
2025-08→2027-05·Not yet recruiting
NCT07116012
172 pts·IPF
2019-11→2025-06·Recruiting
+1 more trial
6,679 total pts3 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-01-201.2y agoPh3 Readout· CRC
2025-06-259mo agoPh3 Readout· IPF
2026-06-022mo awayPh3 Readout· DMD
2027-05-021.1y awayPh3 Readout· DMD
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P3
Termina…
P3
Recruit…
P3
Complet…
P3
Not yet…
Catalysts
Ph3 Readout
2025-01-20 · 1.2y ago
CRC
Ph3 Readout
2025-06-25 · 9mo ago
IPF
Ph3 Readout
2026-06-02 · 2mo away
DMD
Ph3 Readout
2027-05-02 · 1.1y away
DMD
RecruitingCompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06320389 | Phase 3 | CRC | Terminated | 1434 | Mayo |
| NCT04122419 | Phase 3 | DMD | Not yet recr... | 2511 | UPCR |
| NCT07116012 | Phase 3 | IPF | Recruiting | 172 | DOR |
| NCT07701304 | Phase 3 | DMD | Completed | 2562 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| ARG-1250 | Argenx | Phase 2 | C5 |